NSE/BSE Codes: NSE: EMCURE, BSE: 544210
Summary of Key Information:
Nature of Event / Disclosure:
Regulatory disclosure under Regulation 30 of SEBI Listing Regulations regarding income tax penalty orders received from the Income-tax Department.
Involved Parties / Authorities:
- Deputy Commissioner of Income tax, Central Circle 2 (1), Pune (Income-tax Department)
- Emcure Pharmaceuticals Limited (the Company)
Date / Timeline of Event:
- Date of initiation of litigation/dispute: December 27, 2023
- Orders received date: Disclosed on October 2, 2026 (filing date)
- Period covered: Financial Year 2014-15 to Financial Year 2020-21 (Assessment Year 2015-16 to Assessment Year 2021-22)
Brief Description of Outcome / Dispute:
The Income-tax Department has imposed an aggregate penalty of ₹57,73,96,732 (₹57.74 crore) on Emcure Pharmaceuticals Limited for ongoing litigations related to assessment years 2015-16 through 2021-22.
Impact of Outcome:
Financial Impact:
- Direct financial impact: ₹57,73,96,732 (₹57.74 crore) aggregate penalty
- The penalty affects the company's financial statements for the period in which it is recognized
- Impact timeframe: Covers seven financial years from FY2014-15 to FY2020-21
Operational / Business / Strategic Impact:
No material disclosures in this section regarding operational, business, or strategic impacts.
Other Implications:
The company has disclosed this as part of its ongoing litigations in the Integrated Governance Reports, with the latest disclosure being for the quarter ended June 30, 2026.
Next Steps / Required Actions:
- The company is evaluating appropriate legal remedies
- Planning to file an appeal before the Appellate Authority
- Compliance with SEBI Listing Regulations disclosure requirements completed